Pfizer stock rises after aligning with Trump on drug pricing

1. oktober 2025 Rapporteret af AI

Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.

Lawsuits claim Tylenol use in pregnancy causes autism

2. oktober 2025 Rapporteret af AI

More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.

Trump unveils drug pricing deal with AstraZeneca

President Donald Trump announced a deal with AstraZeneca on Friday, offering discounts on medicines for Medicaid in exchange for tariff relief. This follows a similar agreement with Pfizer last week as part of efforts to lower U.S. prescription drug prices. The White House aims to use these pacts as a model for negotiations with other drugmakers.

FDA Grants Accelerated Approval for First Barth Syndrome Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Forzinity, the first treatment for Barth syndrome, a rare X-linked genetic disorder primarily affecting males. Developed by Stealth Biotherapeutics, the therapy targets mitochondrial dysfunction underlying the condition, offering new hope for patients with this life-threatening disease. This milestone follows years of advocacy and highlights progress in addressing ultra-rare disorders.